472 related articles for article (PubMed ID: 32245480)
1. The effect of comprehensive rehabilitation program plus chemotherapy on quality of life in patients with postoperative non-small-cell lung cancer: study protocol of a multicenter randomized clinical trial.
Yao J; Jiao L; Yao Y; Lu Y; Shi J; Li J; Chen P; Xu L; Gong Y
Trials; 2020 Apr; 21(1):309. PubMed ID: 32245480
[TBL] [Abstract][Full Text] [Related]
2. Multi-center randomized double-blind controlled clinical study of chemotherapy combined with or without traditional Chinese medicine on quality of life of postoperative non-small cell lung cancer patients.
Xu L; Li H; Xu Z; Wang Z; Liu L; Tian J; Sun J; Zhou L; Yao Y; Jiao L; Su W; Guo H; Chen P; Liu J
BMC Complement Altern Med; 2012 Aug; 12():112. PubMed ID: 22853619
[TBL] [Abstract][Full Text] [Related]
3. Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial.
Yang XB; Wu WY; Long SQ; Deng H; Pan ZQ; He WF; Zhou YS; Liao GY; Li QP; Xiao SJ; Cai JZ
Trials; 2015 Apr; 16():146. PubMed ID: 25873045
[TBL] [Abstract][Full Text] [Related]
4. Combination of first-line chemotherapy with Kanglaite injections versus first-line chemotherapy alone for advanced non-small-cell lung cancer: study protocol for an investigator-initiated, multicenter, open-label, randomized controlled trial.
Gao R; Zhang Y; Hou W; Li J; Zhu G; Zhang X; Xu B; Wu Z; Wang H
Trials; 2021 Mar; 22(1):214. PubMed ID: 33731199
[TBL] [Abstract][Full Text] [Related]
5. Traditional Chinese Medicine Treatment as Adjuvant Therapy in Completely Resected Stage IB-IIIA Non-Small-Cell Lung Cancer: Study Protocol for a Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.
Jiang Y; Liu LS; Shen LP; Liu JX; Jiang GN; Gu AQ; Li HC; Li Q; Li HG; Huang PX
Clin Lung Cancer; 2019 Sep; 20(5):e541-e547. PubMed ID: 31230892
[TBL] [Abstract][Full Text] [Related]
6. Chinese Herbal Medicine for Improving Quality of Life Among Nonsmall Cell Lung Cancer Patients: Overview of Systematic Reviews and Network Meta-Analysis.
Wu X; Chung VCH; Lu P; Poon SK; Hui EP; Lau AYL; Balneaves LG; Wong SYS; Wu JCY
Medicine (Baltimore); 2016 Jan; 95(1):e2410. PubMed ID: 26735544
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of Jianpishengsui for chemotherapy-related fatigue in patients with non-small cell lung cancer: study protocol for a randomized placebo-controlled clinical trial.
Xiao Z; Hu L; Lin J; Lu L; Huang X; Zhu X; Teo C; Lin L
Trials; 2020 Jan; 21(1):94. PubMed ID: 31948475
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive TCM treatments combined with chemotherapy for advanced non-small cell lung cancer: A randomized, controlled trial.
Xiao Z; Chen Z; Han R; Lu L; Li Z; Lin J; Hu L; Huang X; Lin L
Medicine (Baltimore); 2021 May; 100(18):e25690. PubMed ID: 33950949
[TBL] [Abstract][Full Text] [Related]
9. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.
Yue D; Xu S; Wang Q; Li X; Shen Y; Zhao H; Chen C; Mao W; Liu W; Liu J; Zhang L; Ma H; Li Q; Yang Y; Liu Y; Chen H; Wang C
Lancet Respir Med; 2018 Nov; 6(11):863-873. PubMed ID: 30150014
[TBL] [Abstract][Full Text] [Related]
10. Effects of traditional Chinese medicine combined with chemotherapy for extensive-stage small-cell lung cancer patients on improving oncologic survival: study protocol of a multicenter, randomized, single-blind, placebo-controlled trial.
Chen Y; Yu M; Liu Z; Zhang Y; Li Q; Yang G
Trials; 2021 Jul; 22(1):437. PubMed ID: 34238342
[TBL] [Abstract][Full Text] [Related]
11. Chinese herbal medicine as maintenance therapy for improving the quality of life for advanced non-small cell lung cancer patients.
Han Y; Wang H; Xu W; Cao B; Han L; Jia L; Xu Y; Zhang Q; Wang X; Zhang G; Yu M; Yang G
Complement Ther Med; 2016 Feb; 24():81-9. PubMed ID: 26860807
[TBL] [Abstract][Full Text] [Related]
12. The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).
Zhang Z; Luo F; Zhang Y; Ma Y; Hong S; Yang Y; Fang W; Huang Y; Zhang L; Zhao H
Cancer Commun (Lond); 2019 Nov; 39(1):69. PubMed ID: 31699150
[TBL] [Abstract][Full Text] [Related]
13. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
[TBL] [Abstract][Full Text] [Related]
14. A multicenter randomized controlled trial to assess the efficacy of cancer green therapy in treatment of stage IIIb/IV non-small cell lung cancer.
Sun M; Zhou T; Fang X; Wang D; Pang H; Chen Y; Hu K
Medicine (Baltimore); 2020 Aug; 99(33):e21626. PubMed ID: 32872022
[TBL] [Abstract][Full Text] [Related]
15. Systematic review and meta-analysis of Chinese herbal medicine as adjuvant treatment in advanced non-small cell lung cancer patients.
Wang LC; Chang YY; Lee IC; Kuo HC; Tsai MY
Complement Ther Med; 2020 Aug; 52():102472. PubMed ID: 32951722
[TBL] [Abstract][Full Text] [Related]
16. Effect of gefitinib plus Chinese herbal medicine (CHM) in patients with advanced non-small-cell lung cancer: a retrospective case-control study.
Yang XB; Wu WY; Long SQ; Deng H; Pan ZQ
Complement Ther Med; 2014 Dec; 22(6):1010-8. PubMed ID: 25453521
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of Radical Resected NSCLC by Chinese Medicine Combined with Adjuvant Chemother- apy: a Clinical Study].
Hou WX; Li HG; Chen ZW; Zhu LH; Zhao LH; Tian JH; Xu WJ; Zhou L; Yao YL
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2015 Jun; 35(6):648-53. PubMed ID: 26242112
[TBL] [Abstract][Full Text] [Related]
18. Could Jinfukang alleviate the chemotherapy-related adverse effects in non-small cell lung cancer patients?: A protocol for a double-blind, randomized controlled trial.
Zheng X; Wang W; Wang G; Liu S
Medicine (Baltimore); 2021 Jul; 100(28):e25002. PubMed ID: 34260519
[TBL] [Abstract][Full Text] [Related]
19. Yifei Sanjie Formula or Placebo With Anlotinib as Second-Line or Above Treatment for Metastatic Non-Small-Cell Lung Cancer: Study Protocol for a Double-Blind, Placebo-Controlled Randomized Pilot Study.
Chen W; Lin J; Yang T; Xin Zhang Z; Tao L; Xiao Z; Chen H; Qi X; Sun L; Cao Y; Lin L
Integr Cancer Ther; 2023; 22():15347354221151147. PubMed ID: 36710490
[TBL] [Abstract][Full Text] [Related]
20. Oral Chinese herbal medicine (CHM) as an adjuvant treatment during chemotherapy for non-small cell lung cancer: A systematic review.
Chen S; Flower A; Ritchie A; Liu J; Molassiotis A; Yu H; Lewith G
Lung Cancer; 2010 May; 68(2):137-45. PubMed ID: 20015572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
